The Effect of High-frequency Repetitive Transcranial Magnetic Stimulation on Reducing Depression and Anxiety in Methamphetamine Users

Nastaran Mansouriyeh1, Majid Mahmoud-Aliloo2, Reza Rostami3

Abstract

Background: Methamphetamine use has been associated with higher rates of depression and anxiety. The mesocorticolimbic dopaminergic reward system seems to play a crucial role in inducing depression and anxiety in methamphetamine users. High-frequency repetitive transcranial magnetic stimulation (rTMS) has been shown to alter dopaminergic neurotransmission considering the acute rewarding and reinforcing effects in the subcortical structure. The aim of this study was to investigate the efficacy of rTMS in reducing depression and anxiety symptoms in methamphetamine users.

Methods: In a single-subject method with concurrent multiple baseline designs, in 2017, in Iran, eight methamphetamine users were included, which compared 15 days of active versus placebo stimulation and control group. Two subjects received rTMS on the right dorsolateral prefrontal cortex (DLPFC) and two subjects received rTMS on the left DLPFC. We carried out the measurement using the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) before, during, and after 15 and 30 days of the procedure.

Findings: Right and left DLPFC stimulation significantly reduced depression and anxiety, but the reduction of depression and anxiety by the right DLPFC stimulation was noticeable in this study.

Conclusion: High-frequency rTMS is useful for the treatment of depression and anxiety in methamphetamine users.

Keywords: Transcranial magnetic stimulation; Depression; Anxiety; Methamphetamine

Citation: Mansouriyeh N, Mahmoud-Aliloo M, Rostami R. The Effect of High-frequency Repetitive Transcranial Magnetic Stimulation on Reducing Depression and Anxiety in Methamphetamine Users. Addict Health 2020; 12(4): 278-86.
Introduction

It is estimated that 275 million people have used illicit drugs such as amphetamines. Among amphetamines, methamphetamine is the most influential and it carries a higher risk of dependence and mental disorders. Methamphetamine is a lipophilic molecule which exhibits potent action on the sympathetic and the central nervous system (CNS). Despite the fact that a few studies that strictly explore the epidemiological quality assessment of the relationship between psychiatric disorders and methamphetamine dependence have been performed, it has been reported that the majority (~70%) of every convenience sample of methamphetamine users have depression. The use of methamphetamine has a relation to dopaminergic, serotonergic, and noradrenergic transmission and the involvement of a person’s mood. Studies of methamphetamine users involved in treatment showed that the symptoms of anxiety and depression were self-reported by two-thirds of the total number of users. Likewise, a survey of 200 amphetamine users demonstrated that anxiety (63%), depression (64%), paranoia (74%), hallucination (28%), panic attacks (21%), and suicidal thoughts (19%) were common psychological symptoms. The available treatment options for addictive behaviours remain limited to date. Furthermore, the long-term success rates are poor.

Transcranial magnetic stimulation (TMS) is a powerful and non-surgical brain stimulation technique. In addition, it has been proven that TMS is valuable for research and therapeutic applications within the field of psychiatric medicine. Repetitive TMS (rTMS), in which trains of several TMS pulses are delivered using various stimulation patterns, is applied to induce long-lasting alterations, facilitation, or functional disruptions. According to the long-term neurophysiological effects of rTMS, significant and long-lasting behavioural alterations can be induced to specifically bring about reduction of craving and drugs consumption.

The brain reward system consists of fundamental neural pathways, which are involved in motivational and rewarding experiences. In addition, the impaired function of the brain reward system is implicated in both drug addiction and depressive behaviour. Furthermore, studies have reported comorbidity between these two states in both human beings and animals. Similarly, associations among neuronal activity increase in the mesocorticollimbic dopamine (DA) system; the acute rewarding and reinforcing effects of addiction have been established in neurobiological studies of drug abuse. It has also been found that stimulant drugs (such as cocaine and amphetamines) induce a direct increase in DA levels within the mesocorticollimbic circuitry. The mesocorticollimbic circuitry includes DA projections from the cell bodies in ventral tegmental area (VTA) to limbic structures, for instance, from the nucleus accumbens (NAc) to the amygdala, and the hippocampus to the cortical areas such as the orbitofrontal cortex (OFC) and the anterior cingulate. The primary hypothesis on depression that has been proposed in the last three decades shows that the main symptoms of depression are due to the functional deficiency of the brain’s monoaminergic transmitters’ DA. In the same way, certain research and clinical tests have proved that the impaired functionality of integrated neural pathways (linking select cortical, subcortical, and limbic sites with their related molecular mediators) may be derived from depression. The effects of rTMS on dopaminergic neurotransmission and cortical excitability show that such a tool can be employed in the research and treatment of DA activity and altered cortical excitability in conditions such as depression and addiction.

With respect to the phenomenon of high-frequency rTMS altering dopaminergic neurotransmission, the acute rewarding and reinforcing effects in the subcortical structure have been shown. Whether or not 10-Hz rTMS in 15 sessions with 3500 pulses is able to reduce depression and anxiety in methamphetamine users has to be investigated. Do these effects last one month after treatment? In addition, does stimulation over the right or the left dorsolateral prefrontal cortex (DLPFC) have different results in decreasing depression and anxiety in methamphetamine users?

Methods

We studied eight right-handed men with a mean age of 27.5 years (range: 18-35 years) in 2017, in Iran, fulfilling the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criterion for methamphetamine dependence.
Patients with a history of neurological disease, on medication, on abnormal physical examination, having experienced seizures, having brain damage, having bipolar disease, possessing psychotic symptoms, having metal implants, being pregnant or potentially pregnant, and those who failed to meet the published criteria for TMS safety24 or those who experienced rTMS treatments previously were excluded from this study.

Each session consisted of 3500 total pulses. The frequency was 10 Hz, the duration was five second, and the intensity was 110% of the individual’s motor threshold with coil 8, with five working days “on” and two weekend days “off” design. The safeties of these parameters have been previously described in psychiatric populations.25 Our study was a single-subject method with concurrent multiple baseline designs. Eight subjects were assigned randomly: two subjects underwent right DLPFC stimulation, two subjects underwent left DLPFC stimulation, two subjects were exposed to placebo stimulation, and two subjects were in the control group. These areas were located using the 10-20 system.

The patients were asked to complete the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) for the four sessions at baseline before rTMS. When the score results were stable, the patients had 15 sessions of rTMS. Each of the BAI and BDI inventories was completed after 1, 3, 7, 10, 13, and 15 sessions, and followed up after 15 and 30 days following the completion of rTMS. The outcome measurements were analysed separately for the left, the right, the placebo, and the control groups with descriptive statistics including charts as well as analysis methods based on the Reliable Change Index (RCI) and the effect size. No side effects were reported during the study and the follow-up.

**Results**

Table 1 contains the demographic characteristics of the patients. Tables 2 and 3 contain the score results of eight patients, which have been extracted from the BDI and the BAI. More specifically, the baseline scores, the scores during rTMS stimulation, and the follow-up scores were extracted. Moreover, RCI or the difference between the last rTMS session and the baseline was calculated. In addition, RCI for the comparison of the final baseline with the scores extracted in the next month were demonstrated. It is clear that the efficacy percentages in the placebo and the control groups with the calculations of RCI are in reverse. On the other hand, the advantages in the experimental groups for recuperation, i.e., 24% to 60% in depression and 9% to 84% in anxiety, were demonstrated.

As shown in tables 4 and 5, the descriptive statistical results were calculated with the effect size. The changes of the effect size of baseline-treatment stage and the effect size of treatment stage-follow up, citing the BDI and the BAI for the first, second, fourth, and fifth subjects, were significant.

Participants were satisfied and informed consent was obtained from all participants included in the study. The written informed consent was obtained from the patients for publication of this study.

**Discussion**

The main objective of this study was to consider the efficacy of rTMS in reducing depression and anxiety symptoms in methamphetamine users. In addition, the effect of rTMS on both the left and the right DLPFC was regarded.

The experimental results demonstrated that a high-frequency (10 Hz) rTMS led to desirable effects in decreasing depression and anxiety in methamphetamine users. Clearly, previous research results are supported by the consequences of the proposed approach.10,22,26,27

---

**Table 1. Demographic characteristics**

| Case | Gender | Age (year) | Job       | Education             | Single/married | Group               |
|------|--------|------------|-----------|-----------------------|----------------|---------------------|
| 1    | Male   | 34         | Unemployed| Secondary school      | Single         | Experimental left DLPFC |
| 2    | Male   | 28         | Unemployed| Associate's degree    | Single         | Experimental left DLPFC |
| 3    | Male   | 25         | Unemployed| Associate's degree    | Single         | Placebo left DLPFC   |
| 4    | Male   | 27         | Unemployed| Diploma               | Single         | Experimental right DLPFC |
| 5    | Male   | 31         | Unemployed| Diploma               | Single         | Experimental right DLPFC |
| 6    | Male   | 27         | Unemployed| Associate's degree    | Single         | Placebo right DLPFC  |
| 7    | Male   | 22         | Unemployed| Diploma               | Single         | Control              |
| 8    | Male   | 26         | Unemployed| Bachelor's degree     | Single         | Control              |

DLPFC: Dorsolateral prefrontal cortex
Table 2. Descriptive analyses of Beck Depression Inventory (BDI)

| Case | Before rTMS | Before rTMS | Before rTMS | After 1 session of rTMS | After 3 sessions of rTMS | After 7 sessions of rTMS | After 10 sessions of rTMS | After 13 sessions of rTMS | After 15 sessions of rTMS | Follow-up (15 days) | Follow-up (30 days) | Between last baseline and session 15 of rTMS | Between last baseline and follow-up (30 days) |
|------|-------------|-------------|-------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|---------------------|---------------------|---------------------------------|---------------------------------|
| 1    | 29          | 26          | 25          | 25                     | 19                     | 20                     | 19                     | 24                     | 19                     | 19                  | 10                  | 10                | 24                |
| 2    | 25          | 20          | 25          | 27                     | 25                     | 24                     | 27                     | 25                     | 26                     | 14                  | 13                  | 13                | 48                |
| 3    | 52          | 53          | 50          | 51                     | 53                     | 60                     | 48                     | 48                     | 51                     | 51                  | 51                  | 51                | -                 |
| 4    | 13          | 27          | 26          | 26                     | 18                     | 25                     | 18                     | 18                     | 14                     | 14                  | 12                  | 12                | 46                |
| 5    | 18          | 21          | 26          | 26                     | 26                     | 25                     | 20                     | 18                     | 14                     | 14                  | 14                  | 14                | 46                |
| 6    | 40          | 40          | 40          | 40                     | 42                     | 39                     | 27                     | 39                     | 40                     | 40                  | 41                  | 40                | -                 |
| 7    | 26          | 25          | 27          | 28                     | 30                     | 28                     | 32                     | 34                     | 32                     | 31                  | 32                  | 31                | -                 |
| 8    | 27          | 26          | 26          | 27                     | 26                     | 25                     | 27                     | 25                     | 27                     | 27                  | 26                  | 27                | -                 |

rTMS: Repetitive transcranial magnetic stimulation; RCI: Reliable Change Index

Table 3. Descriptive analyses of Beck Anxiety Inventory (BAI)

| Case | Before rTMS | Before rTMS | Before rTMS | After 1 session of rTMS | After 3 sessions of rTMS | After 7 sessions of rTMS | After 10 sessions of rTMS | After 13 sessions of rTMS | After 15 sessions of rTMS | Follow-up (15 days) | Follow-up (30 days) | Between last baseline and session 15 of rTMS | Between last baseline and follow-up (30 days) |
|------|-------------|-------------|-------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|---------------------|---------------------|---------------------------------|---------------------------------|
| 1    | 23          | 15          | 15          | 15                     | 11                     | 8                      | 11                     | 17                     | 11                     | 10                  | 10                  | 9                 | 9                 |
| 2    | 11          | 4           | 3           | 2                      | 3                      | 4                      | 4                      | 6                      | 4                      | 2                   | 2                   | 66                | 66                |
| 3    | 13          | 19          | 18          | 7                      | 6                      | 6                      | 17                     | 11                     | 25                     | 10                  | 15                  | -                 | -                 |
| 4    | 35          | 30          | 10          | 6                      | 3                      | 4                      | 3                      | 6                      | 3                      | 2                   | 2                   | 76                | 84                |
| 5    | 10          | 12          | 15          | 7                      | 8                      | 8                      | 10                     | 10                     | 8                      | 8                   | 8                   | 73                | 73                |
| 6    | 26          | 16          | 17          | 18                     | 20                     | 20                     | 19                     | 20                     | 20                     | 18                  | 18                  | -                 | -                 |
| 7    | 25          | 12          | 20          | 25                     | 26                     | 25                     | 20                     | 20                     | 20                     | 25                  | 25                  | -                 | -                 |
| 8    | 23          | 15          | 15          | 15                     | 11                     | 8                      | 11                     | 17                     | 11                     | 10                  | 10                  | 9                 | 9                 |

rTMS: Repetitive transcranial magnetic stimulation; RCI: Reliable Change Index
### Table 4. Effect size on decrease of depression scores

| Case | Average of baseline scores | Average of treatment stage scores | Average of follow-up scores | SD of baseline scores | SD of treatment stage scores | SD of follow-up scores | Effect size of baseline-treatment stage | Effect size of treatment stage-follow up |
|------|-----------------------------|----------------------------------|-----------------------------|-----------------------|-----------------------------|------------------------|----------------------------------------|------------------------------------------|
| 1    | 26.25                       | 20.00                            | 10.00                       | 1.89                  | 2.00                        | 0                      | 3.08                                   | 5.00                                     |
| 2    | 24.25                       | 23.50                            | 13.00                       | 2.98                  | 4.76                        | 0                      | 0.33                                   | 2.62                                     |
| 3    | 51.50                       | 51.83                            | 51.00                       | 1.29                  | 4.44                        | 0                      | -                                      | -                                        |
| 4    | 23.00                       | 17.83                            | 12.00                       | 6.68                  | 4.02                        | 0                      | 1.20                                   | 1.20                                     |
| 5    | 22.75                       | 19.50                            | 14.00                       | 3.69                  | 5.20                        | 0                      | 0.75                                   | 1.00                                     |
| 6    | 40.00                       | 37.83                            | 40.50                       | 0                     | 5.41                        | 0.70                   | -                                      | -                                        |
| 7    | 26.50                       | 31.16                            | 31.50                       | 1.29                  | 2.04                        | 0.70                   | -                                      | -                                        |
| 8    | 26.50                       | 26.16                            | 26.50                       | 0.57                  | 0.98                        | 0.70                   | -                                      | -                                        |

SD: Standard deviation

### Table 5. Effect size on decrease of anxiety scores

| Case | Average of baseline scores | Average of treatment stage scores | Average of follow-up scores | SD of baseline scores | SD of treatment stage scores | SD of follow-up scores | Effect size of baseline-treatment stage | Effect size of treatment stage-follow up |
|------|-----------------------------|----------------------------------|-----------------------------|-----------------------|-----------------------------|------------------------|----------------------------------------|------------------------------------------|
| 1    | 16.00                       | 12.16                            | 10.00                       | 5.03                  | 3.25                        | 0.70                   | 1.00                                   | 0.66                                     |
| 2    | 6.00                        | 3.83                             | 2.00                        | 3.55                  | 1.32                        | 1.41                   | 1.50                                   | 1.00                                     |
| 3    | 14.75                       | 12.00                            | 12.50                       | 4.64                  | 7.64                        | 10.60                  | -                                      | -                                        |
| 4    | 22.00                       | 4.16                             | 2.00                        | 12.35                 | 1.47                        | 0.70                   | 2.57                                   | 2.00                                     |
| 5    | 16.75                       | 8.50                             | 8.00                        | 9.06                  | 1.22                        | 0                      | 1.60                                   | 0                                        |
| 6    | 18.25                       | 19.50                            | 18.00                       | 5.31                  | 0.83                        | 1.41                   | -                                      | -                                        |
| 7    | 19.75                       | 22.66                            | 25.00                       | 5.50                  | 2.90                        | 3.53                   | -                                      | -                                        |
| 8    | 23.75                       | 26.00                            | 25.50                       | 2.80                  | 1.60                        | 0.70                   | -                                      | -                                        |

SD: Standard deviation
The long-term effects of rTMS on dopaminergic neurotransmission and cortical excitability suggest that such a tool can be used on methamphetamine users. DLPFC has been identified as the main target for stimulation in depression and addiction.8

There are several mechanisms that have been proposed for explaining the effects of rTMS on the DLPFC. Firstly, the stimulation of the DLPFC can induce releases of DA in the subcortical structure and the caudate nucleus.29,30 Secondly, the effect of brain stimulation can extend beyond directly-targeted areas, including cross-hemispheric cortical and subcortical activity in remote neural networks connected to the stimulated regions.27 Furthermore, a study using combined rTMS/positron emission tomography (PET) reported an elevation in the extracellular DA concentration, following the 10-Hz rTMS administered to the DLPFC.30 Associations between methamphetamine users and increased levels of depression are known.5,31 In this regard, rTMS has shown great promise for medication-resistant patients who suffer from depression and substance use disorder (SUD).22,26,27

The effects of TMS on cortical excitability are immensely dependent on stimulation parameters. Variations in stimulation parameters include the following: the orientation of the magnetic field, single or repetitive stimulation and the frequency of stimulation, the number of pulses, and the intensity and the site of stimulation.32 In previous studies, the positive effects of rTMS on depression have been reported. Likewise, the current research demonstrated that 10-Hz rTMS had desirable effects on depression in methamphetamine users. Stimulation intensity is another fundamental parameter in rTMS, which has been reported as a key parameter of the occurring long-term potential (LTP) in most studies.33 Owing to the significant functionality of rTMS in making long-term alterations in cortical excitability and better treatment probability, in this study, the stimulation intensity is assumed as 110% of patient's motor threshold, in which the motor-evoked potential (MEP) is used. In addition, the lasting treatment effects of rTMS are considered. The experimental results demonstrated that these effects lasted beyond a month. Obviously, following up the lasting effects had some limitations and was, therefore, impossible. Long-term follow-up with more instances is thus necessary.

Including the control and the placebo groups is the most considerable advantage of the current research, in which, the experimental groups had better treatment effects in comparison to the placebo and the control groups. An important factor that can influence rTMS treatment is handedness, so right-handed men were elected. Owing to the variety of cortical anatomy types and the various viewpoints about the stimulation area, the effects of rTMS over the right and the left DLPFC on depression, anxiety, and addiction (methamphetamine users) reduction are studied in this research.

Several studies applied high-frequency (10-20 Hz) rTMS on the left prefrontal cortex (PFC). Consequently, their efficacy in depression treatment has already been demonstrated.34 On the other hand, the right DLPFC rTMS induced significant changes in conditions of anxiety and happiness over time. However, the left DLPFC stimulation induced significant changes in sadness over time.22 In addition, it has been demonstrated that low-frequency (1 Hz) rTMS in the right DLPFC is applicable for depression.27 Functional imaging suggests that the right PFC serves a critical function in risky-behaviour regulation.35 Further studies showed that increasing happiness enhanced risky-behaviour regulation after right PFC rTMS.36 In addition, several human studies have begun to evaluate the effects of rTMS protocols employed on the PFC in regard to drug craving, and nicotine- and cocaine-dependent groups.

Despite the fact that high-frequency rTMS of the left DLPFC reduced drug consumption, the craving levels remained fixed.27 It also has been empirically proved that a single session of high-frequency rTMS can significantly reduce cocaine craving when applied to the right, but not the left PFC. Moreover, anxiety was significantly reduced after right-sided stimulation. Furthermore, happiness was increased after right- and sadness was increased after left-sided stimulation.27 In contrast, other rTMS had no effect on depression and addiction or the effects were undesirable.

**Conclusion**

In contrast with these disputed studies’ results which are mentioned above, rTMS over both the right and the left DLPFC caused a reduction of
depression and anxiety in methamphetamine users. The outstanding feature of the current study was the significant effect of 10-Hz rTMS on the right DLPFC in reducing depression and anxiety in methamphetamine users.

It is apparent that there is a direct relationship between craving and drug use; therefore, decreasing craving will reduce drug use. As a consequence, a reduction in craving will enhance social communication and self-confidence, through which, a person’s happiness and his depression level will be, respectively, increased and decreased. On the other hand, high-frequency rTMS on the right DLPFC may reduce depression. It is thus suggested that the reason behind decreasing depression should be considered in further research. Further studies will expand the knowledge of the neuro-anatomical structure of methamphetamine users. Consequently, the effective elements of the pathophysiological mood process of these patients will be discovered.

Limitations: In this study, self-reporting questionnaires were used to collect information; as such, this method of information collection can affect the generalization of the results. A sample of a city is selected, which is suggested to be similar to study in cities and other examples used to enhance the overall nature of the findings.

Conflict of Interests
The Authors have no conflict of interest.

Acknowledgements
The authors would like to thank all the patients who participated in this study.

Authors’ Contribution
Conceptualization, data curation, data analysis funding, investigation, methodology, software, data curation, supervision, writing-original draft, writing, review and editing: NM; supervision: MMA; adviser, head of the rTMS clinic: RR.

References

1. Vocci FJ, Montoya ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr Opin Psychiatry 2009; 22(3): 263-8.
2. World Health Organization, WHO Expert Committee on Drug Dependence. WHO Technical Report Series 998. Geneva, Switzerland: WHO; 2016.
3. Zarrabi H, Khalkhali M, Hamidi A, Ahmadi R, Zavarnousavi M. Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients. BMC Psychiatry 2016; 16: 44.
4. Moszcynska A, Callan SP. Molecular, behavioral, and physiological consequences of methamphetamine neurotoxicity: implications for treatment. J Pharmacol Exp Ther 2017; 362(3): 474-88.
5. Ferrucci M, Limanaqi F, Ryskalin L, Biagioni F, Busceti CL, Fornai F. The effects of amphetamine and methamphetamine on the release of norepinephrine, dopamine and acetylcholine from the brainstem reticular formation. Front Neuroanat 2019; 13: 48.
6. Vincent N, Schoobridge J, Ask A, Allsop S, Ali R. Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. Drug Alcol Rev 1998; 17(2): 187-95.
7. Pettersen H, Landheim A, Skeie I, Biong S, Brodahl M, Benson V, et al. Helpful ingredients in the treatment of long-term substance use disorders: A collaborative narrative study. Subst Abuse 2019; 13: 1178221819844996.
8. Gorelick DA, Zangen A, George MS. Transcranial magnetic stimulation in the treatment of substance addiction. Ann N Y Acad Sci 2014; 1327: 79-93.
9. Bellamoli E, Manganotti P, Schwartz RP, Rimondo C, Gomma M, Serpelloni G. rTMS in the treatment of drug addiction: An update about human studies. Behav Neurol 2014; 2014: 815215.
10. Wagner T, Valero-Cabrera A, Pascual-Leone A. Noninvasive human brain stimulation. Annu Rev Biomed Eng 2007; 9: 527-65.
11. Feil J, Zangen A. Brain stimulation in the study and treatment of addiction. Neurosci Biobehav Rev 2010; 34(4): 559-74.
12. Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, Robbins TW. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci 2008; 363(1507): 3125-35.
13. Feltenstein MW, See RE. The neurocircuitry of addiction: An overview. Br J Pharmacol 2008; 154(2): 261-74.
14. Enoch MA. The role of GABA(A) receptors in the development of alcoholism. Pharmacol Biochem Behav 2008; 90(1): 95-104.
15. Di Chiara G. Nucleus accumbens shell and core dopamine: Differential role in behavior and addiction. Behav Brain Res 2002; 137(1-2): 75-114.
16. Meil WM, See RE. Lesions of the basolateral amygdala abolish the ability of drug associated cues to reinitiate responding during withdrawal from self-administered cocaine. Behav Brain Res 1997; 87(2): 139-48.
17. Robbins TW, Ersche KD, Everitt BJ. Drug addiction and the memory systems of the brain. Ann N Y Acad Sci 2008; 1141: 1-21.
18. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology and treatment of major depressive disorder. In: Iversen L, Iversen S, Dunnett S, Bjorklund A, editors. Dopamine handbook. Oxford, UK: Oxford University Press; 2010.
19. Dichter GS, Damiano CA, Allen JA. Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: Animal models and clinical findings. J Neurodev Disord 2012; 4(1): 19.
20. Lang N, Hasan A, Sueske E, Paulus W, Nitsche MA. Cortical hypoexcitability in chronic smokers? A transcranial magnetic stimulation study. Neuropsychopharmacology 2008; 33(10): 2517-23.
21. Sundaresan K, Ziemann U, Stanley J, Boutros N. Cortical inhibition and excitation in abstinent cocaine-dependent patients: A transcranial magnetic stimulation study. Neuroreport 2007; 18(3): 289-92.
22. Amiaz R, Levy D, Vainiger D, Grunhaus L, Zangen A. Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption. Addiction 2009; 104(4): 653-60.
23. Grall-Bronnec M, Sauvaget A. The use of repetitive transcranial magnetic stimulation for modulating craving and addictive behaviours: A critical literature review of efficacy, technical and methodological considerations. Neurosci Biobehav Rev 2014; 47: 592-613.
24. Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: Report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol 1998; 108(1): 1-16.
25. Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 1996; 348(9022): 233-7.
26. Terraneo A, Leggio L, Saladini M, Ermani M, Bonci A, Galliamberti L. Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study. Eur Neuropsychopharmacol 2016; 26(1): 37-44.
27. Camprodon JA, Martinez-Raga J, Alonso-Alonso M, Shih MC, Pascual-Leone A. One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving. Drug Alcohol Depend 2007; 86(1): 91-4.
28. Fitzgerald PB, Daskalakis ZJ. The effects of repetitive transcranial magnetic stimulation in the treatment of depression. Expert Rev Med Devices 2011; 8(1): 85-95.
29. Chib VS, Yun K, Takahashi H, Shimojo S. Noninvasive remote activation of the ventral midbrain by transcranial direct current stimulation of prefrontal cortex. Transl Psychiatry 2013; 3: e268.
30. Fitzgerald PB, Brown TL, Daskalakis ZJ, Chen R, Kulkarni J. Intensity-dependent effects of 1 Hz rTMS on human corticospinal excitability. Clin Neurophysiol 2002; 113(7): 1136-41.
31. McKetin R, Lubman DI, Lee NM, Ross JE, Slade TN. Major depression among methamphetamine users entering drug treatment programs. Med J Aust 2011; 195(3): 51-5.
32. George MS, Post RM. Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression. Am J Psychiatry 2011; 168(4): 356-64.
33. Erhardt A, Sillaber I, Welt T, Muller MB, Singewald N, Keck ME. Repetitive transcranial magnetic stimulation increases the release of dopamine in the nucleus accumbens shell of morphine-sensitized rats during abstinence. Neuropsychopharmacology 2004; 29(11): 2074-80.
34. Levy D, Shabat-Simon M, Shalev U, Barnea-Ygael N, Cooper A, Zangen A. Repeated electrical stimulation of reward-related brain regions affects cocaine but not "natural" reinforcement. J Neurosci 2007; 27(51): 14179-89.
35. Jung SH, Shin JE, Jeong YS, Shin HI. Changes in motor cortical excitability induced by high-frequency repetitive transcranial magnetic stimulation of different stimulation durations. Clin Neurophysiol 2008; 119(1): 71-9.
36. Fishbein DH, Eldredh DL, Hyde C, Matochik JA, London ED, Contoreggi C, et al. Risky decision making and the anterior cingulate cortex in abstinent drug abusers and nonusers. Brain Res Cogn Brain Res 2005; 23(1): 119-36.
37. Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol 2006; 9(1): 95-100.
بررسی کاهش افسردگی و اضطراب به وسیله تحریک مکرر مغناطیسی فراشري با فرکانس بالا در مصرف کندگان متآمفتامین

چکیده
مقدمه: مصرف متآمفتامین با میزان بالای افسردگی و اضطراب مرتبط است. به نظر می‌رسد سیستم دوبامینرژیک مزکورتیولوکوسیمیک نقش اساسی در ایجاد افسردگی و اضطراب در مصرف کندگان متآمفتامین دارد. تحریک مکرر مغناطیسی فراشري با فرکانس بالا با توجه به اثرات شدید پاداشی و تقویت کندگان در اختلال‌های افسردگی متفاوت اثرات مثبتی را نشان می‌دهد. هدف از انجام پژوهش حاضر، تأثیر تحریک مکرر مغناطیسی فراشري در کاهش علائم افسردگی و اضطراب در مصرف کندگان متآمفتامین بود.

روش ها: در یک روش تک آزمونی با خط پایه چندگانه همزمان در سال 1395، در ایران، 8 مصرف کننده متآمفتامین شامل 15 جلسه تحریک گروه آزمایشی و گروه کنترل با فرکانس بالا روزانه دو بار قادر بودند. دو نفر تحریک مکرر مغناطیسی فراشري در ناحیه قشر پشتی پشتی پشتی پشتی چپ را دریافت کردند. اندازه‌گیری‌ها با استفاده از پرسش‌نامه (BAI) یا (Beck Anxiety Inventory) و (BDI) یا (Beck Depression Inventory) در پیشینه بیشترین دریافت کردن انجام گرفت. اندازه‌گیری‌ها پس از ۱۵ و ۳۰ روز انجام شد.

یافته‌ها: تحریک مکرر مغناطیسی فراشري در دو ناحیه قشر پشتی پشتی راست و چپ به طور معنی‌داری افسردگی و اضطراب را کاهش داد. اما کاهش افسردگی و اضطراب توسط تحریک در ناحیه قشر پشتی راست و چپ را قابل توجه بود.

نتیجه گیری: تحقیق مکرر مغناطیسی فراشري با فرکانس بالا برای درمان افسردگی و اضطراب در مصرف کندگان متآمفتامین مفید است.

واژگان کلیدی: تحقیق مکرر مغناطیسی فراشري، افسردگی، اضطراب، متآمفتامین

ارجاع: منصوریه نسترن، محمدرضا علی‌یه. بررسی کاهش افسردگی و اضطراب به وسیله تحریک مکرر مغناطیسی فراشري با فرکانس بالا در مصرف کندگان متآمفتامین. مجله اعتیاد و سلامت. 1399(3):278-286.

تاریخ دریافت: 1399/3/9
تاریخ پذیرش: 1399/5/19

Email: n.mansoreye1984@gmail.com

DOI: http://dx.doi.org/10.22122/ahj.v12i4.288
Published by Vesnu Publication

http://ahj.kmu.ac.ir, 06 October